Skip to main content
SpringerLink
Log in

Safety Considerations for Osteoporosis Therapies

  • Chapter
  • First Online:
Osteoporosis

Part of the book series: Contemporary Endocrinology ((COE))

  • 1852 Accesses

Abstract

Osteoporosis therapies have been shown to reduce fracture risk. In this chapter, we will examine the safety considerations for both antiresorptive therapies (such as bisphosphonates, denosumab, hormone replacement therapy, raloxifene) and bone formation therapies (such as teriparatide, abaloparatide, and romosozumab). Potential adverse effects with antiresorptive therapies include gastrointestinal discomfort, acute phase reaction, musculoskeletal pain, ocular complications, atrial fibrillation, hypocalcemia, atypical femur fractures, osteonecrosis of the jaw, and venous thromboembolic events. Potential adverse effects with bone formation therapies include hypercalciuria, hypercalcemia, hyperuricemia, and cardiovascular effects. Patients on bisphosphonate therapy should be reassessed after 3–5 years of therapy to see if they are eligible for a drug holiday. Every medication has potential risks and benefits, and the magnitude of these should be put into perspective. Effective communication of benefits and risks will ensure an evidence-based approach to the treatment of osteoporosis and osteoporotic fractures.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254–62.

    Article  CAS  PubMed  Google Scholar 

  2. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(10):1910.

    Article  CAS  PubMed  Google Scholar 

  3. Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, et al. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician. 2014;60(4):324–33.

    PubMed  PubMed Central  Google Scholar 

  4. Khan M, Cheung AM, Khan AA. Drug-related adverse events of osteoporosis therapy. Endocrinol Metab Clin N Am. 2017;46(1):181–92.

    Article  Google Scholar 

  5. Lewiecki EM, Miller PD, Harris ST, Bauer DC, Davison KS, Dian L, et al. Understanding and communicating the benefits and risks of Denosumab, Raloxifene, and Teriparatide for the treatment of osteoporosis. J Clin Densitom. 2014;17(4):490–5.

    Article  PubMed  Google Scholar 

  6. Qaseem A, Forciea MA, McLean RM, Denberg TD. Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(11):818–39.

    Article  PubMed  Google Scholar 

  7. Richardson RM, Rapoport A, Oreopoulos DG, Meema HE, Rabinovich S. Unusual fractures associated with osteoporosis in premenopausal women. Can Med Assoc J. 1978;119(5):473–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Orwoll ES, McClung MR. Pseudofractures in patients with low turnover osteoporosis. West J Med. 1985;143:239–42. 18.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–301.

    Article  CAS  PubMed  Google Scholar 

  10. Wang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res. 2011;26(3):553–60.

    Article  CAS  PubMed  Google Scholar 

  11. Meier RP, et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med. 2012;172(12):930–6.

    Article  PubMed  Google Scholar 

  12. Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011;305(8):783–9.

    Article  CAS  PubMed  Google Scholar 

  13. Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012;27(12):2544–50.

    Article  PubMed  Google Scholar 

  14. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013;28(8):1729–37.

    Article  CAS  PubMed  Google Scholar 

  15. Koh JH, Myong JP, Yoo J, Lim YW, Lee J, Kwok SK, et al. Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years’ experience in a single center. Osteoporos Int. 2017;28(11):3251–9.

    Article  CAS  PubMed  Google Scholar 

  16. Kim JW, Kim JJ, Byun YS, Shon OJ, Oh HK, Park KC, et al. Factors affecting fracture location in atypical femoral fractures: a cross-sectional study with 147 patients. Injury. 2017;48(7):1570–4.

    Article  PubMed  Google Scholar 

  17. Lo JC, Hui RL, Grimsrud CD, Chandra M, Neugebauer RS, Gonzalez JR, et al. The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone. 2016;85:142–7.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Morin SN, Wall M, Belzile EL, Godbout B, Moser TP, Michou L, et al. Assessment of femur geometrical parameters using EOS imaging technology in patients with atypical femur fractures; preliminary results. Bone. 2016;83:184–9.

    Article  PubMed  Google Scholar 

  19. Qiu S, Divine GW, Palnitkar S, Kulkarni P, Guthrie TS, Honasoge M, et al. Bone structure and turnover status in postmenopausal women with atypical femur fracture after prolonged bisphosphonate therapy. Calcif Tissue Int. 2017;100(3):235–43.

    Article  CAS  PubMed  Google Scholar 

  20. Nguyen HH, van de Laarschot DM, Verkerk AJMH, Milat F, Zillikens MC, Ebeling PR. Genetic risk factors for atypical femoral fractures (AFFs): a systematic review. JBMR Plus. 2018;2(1):1–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Bhattacharyya T, Jha S, Wang H, Kastner DL, Remmers EF. Hypophosphatasia and the risk of atypical femur fractures: a case–control study. BMC Musculoskelet Disord. 2016;17(1):332.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–94.

    Article  PubMed  Google Scholar 

  23. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1–23.

    Article  PubMed  Google Scholar 

  24. Cheung AM, Bleakney R, Ridout R, McDonald-Blumer H, Yau D, Tile L, et al. Detection of incomplete non-displaced atypical femur fractures by densitometer. J Clin Densitom. 2014;17(3):418.

    Article  Google Scholar 

  25. van de Laarschot DM, Smits AAA, Buitendijk SKC, Stegenga MT, Zillikens MC. Screening for atypical femur fractures using extended femur scans by DXA. J Bone Miner Res. 2017;32(8):1632–9.

    Article  PubMed  CAS  Google Scholar 

  26. McKenna MJ, van der Kamp S, Heffernan E, Hurson C. Incomplete atypical femoral fractures: assessing the diagnostic utility of DXA by extending femur length. J Clin Densitom. 2013;16:579–83.

    Article  PubMed  Google Scholar 

  27. Dell R, Greene D. A proposal for an atypical femur fracture treatment and prevention clinical practice guideline. Osteoporos Int. 2018:1–7.

    Google Scholar 

  28. Eisenstein N, Kasavkar G, Bhavsar D, Khan FS, Paskins Z. Incidence and medical management of bisphosphonate-associated atypical femoral fractures in a major trauma centre: a retrospective observational study. BMC Musculoskelet Disord. 2017;18(1):9.

    Article  Google Scholar 

  29. Greenspan SL, Vujevich K, Britton C, Herradura A, Gruen G, Tarkin I, et al. Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur. Osteoporos Int. 2018;29(2):501–6.

    Article  CAS  PubMed  Google Scholar 

  30. Watts NB, Aggers D, McCarthy EF, Savage T, Martinez S, Patterson R, et al. Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates. J Bone Miner Res. 2017;32(5):1027–33.

    Article  CAS  PubMed  Google Scholar 

  31. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104:1595–622.

    Article  PubMed  Google Scholar 

  32. Adami S, Idolazzi L, Fracassi E, Gatti D, Rossini M. Osteoporosis treatment: when to discontinue and when to re-start. Bone Res. 2013;1(4):323–35.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Bindon B, Adams W, Balasubramanian N, Sandhu J, Camacho P. Osteoporotic fractures during bisphosphonate drug holiday. Endocr Pract. 2018;24(2):163–9.

    Article  PubMed  Google Scholar 

  34. Lovy AJ, Koehler SM, Keswani A, Joseph D, Hasija R, Ghillani R. Atypical femur fracture during bisphosphonate drug holiday: a case series. Osteoporos Int. 2015;26(6):1755–8.

    Article  CAS  PubMed  Google Scholar 

  35. Wright NC, Foster PJ, Mudano AS, Melnick JA, Lewiecki ME, Shergy WJ, et al. Assessing the feasibility of the effectiveness of discontinuing bisphosphonates trial: a pilot study. Osteoporos Int. 2017;28(8):2495–503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–91.

    Article  PubMed  Google Scholar 

  37. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus: report from the international ONJ task force. J Bone Miner Res. 2015;30(1):3–23.

    Article  PubMed  Google Scholar 

  38. IBM Micromedex Web Application Access. Retrieved from: https://www.micromedexsolutions.com/micromedex2/librarian/CS/7AF1B8/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/A4E9BE/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.IntermediateToDocumentLink/ssl/true?topicId=null&servicesTitle=RISEDRONATE&contentSetId=31&docId=2365&title=RISEDRONATE. Accessed 24 July 2019.

  39. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(1):89–90.

    Article  CAS  PubMed  Google Scholar 

  40. Green J, et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ. 2010;341:c4444.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Sun K, Liu JM, Sun HX, Lu N, Ning G. Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies. Osteoporos Int. 2013;24(1):279–86.

    Article  CAS  PubMed  Google Scholar 

  42. Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med. 2005;165:346–7.

    Article  PubMed  Google Scholar 

  43. Clark EM, Durup D. Inflammatory eye reactions with bisphosphonates and other osteoporosis medications: what are the risks? Ther Adv Musculoskelet Dis. 2015;7(1):11–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for the treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–22.

    Article  CAS  PubMed  Google Scholar 

  45. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007;356:1895–6.

    Article  CAS  PubMed  Google Scholar 

  46. Barrett-Connor E, Swern AS, Hustad CM, Bone HG, Liberman UA, Papapoulos S, et al. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos Int. 2012;23(1):233–45.

    Article  CAS  PubMed  Google Scholar 

  47. Majumdar SR. Oral bisphosphonates and atrial fibrillation. BMJ. 2008;336(7648):784–5.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007;22(4):503–8.

    Article  CAS  PubMed  Google Scholar 

  49. Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.

    Article  CAS  PubMed  Google Scholar 

  50. Bone HG, Chapurlat R, Brandi M, Brown JP, Czerwiński E, Krieg M, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metabol. 2013;98(11):4483–92.

    Article  CAS  Google Scholar 

  51. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–23.

    Article  CAS  PubMed  Google Scholar 

  52. Watts NB, Brown JP, Papapoulos S, Lewiecki EM, Kendler DL, Dakin P, et al. Safety observations with 3 years of denosumab exposure: comparison between subjects who received denosumab during the randomized FREEDOM trial and subjects who crossed over to denosumab during the FREEDOM extension. J Bone Miner Res. 2017;32(7):1481–5.

    Article  CAS  PubMed  Google Scholar 

  53. King BJ, Lehman JS, Sartori Valinotti JC. Denosumab-induced cutaneous hypersensitivity reaction with distinct clinical and histopathologic findings. J Cutan Pathol. 2018;45(2):156–8.

    Article  PubMed  Google Scholar 

  54. Farooki A, Fornier M, Boland P. Atypical femur fractures associated with use of bisphosphonates and denosumab. Ann Oncol. 2015;26(4):819–20.

    Article  CAS  PubMed  Google Scholar 

  55. Cating-Cabral M, Clarke BL. Denosumab and atypical femur fractures. Maturitas. 2013;76(1):1–2.

    Article  PubMed  Google Scholar 

  56. Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018;6(6):445–54.

    Article  CAS  PubMed  Google Scholar 

  57. Lamy O, Gonzalez-Rodrigues E, Stoll D, Hans D, Aubry-Rozier B. Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab. 2017;102(2):354–8.

    Article  PubMed  Google Scholar 

  58. Florez H, Ramirez J, Monegal A, Guañabens N, Peris P. Spontaneous vertebral fractures after denosumab discontinuation: a case collection and review of the literature. Semin Arthritis Rheum. 2019 Feb 15 e-pub. https://doi.org/10.1016/j.semarthrit.2019.02.007.

    Article  CAS  PubMed  Google Scholar 

  59. Anastasilakis AD, Polyzos SA, Makras P, Aubrey-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 2017;32(6):1291–6.

    Article  CAS  PubMed  Google Scholar 

  60. Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. Vertebral fractures after discontinuation of denosumab: a post-hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):190–8.

    Article  CAS  PubMed  Google Scholar 

  61. Tripto-Shkolnik L, Rouach V, Marcus Y, Rotman-Pikielny P, Benbassat C, Vered I. Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates. Calcif Tissue Int. 2018;103(1):44–9.

    Article  CAS  PubMed  Google Scholar 

  62. Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC. Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11–7.

    Article  PubMed  Google Scholar 

  63. Reid IR, Horne AM, Mihov B, et al. Bone loss after denosumab: only partial protection with zoledronate. Calcif Tissue Int. 2017;101:371–4.

    Article  CAS  PubMed  Google Scholar 

  64. Freemantle N, Satram-Hoang S, Tang ET, et al. Final results of the DAPS (Denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23:317–26.

    Article  CAS  PubMed  Google Scholar 

  65. Karim R, Dell RM, Greene DF, Mack WJ, Gallagher JC, Hodis HN. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause. 2011;18(11):1172–7.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009;360:573–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Chaplin S. NICE guideline: diagnosis and management of the menopause. Prescriber. 2016;27(1):27–32.

    Article  Google Scholar 

  68. Lobo RA. Hormone-replacement therapy: current thinking. Nat Rev Endocrinol. 2016;13(4):220.

    Article  PubMed  CAS  Google Scholar 

  69. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637.

    Article  CAS  PubMed  Google Scholar 

  70. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, et al. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23(4):524–8.

    Article  CAS  PubMed  Google Scholar 

  71. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA. 1999;281(23):2189–97.

    Article  CAS  PubMed  Google Scholar 

  72. Goldstein SR, Duvernoy CS, Calaf J, Adachi JD, Mershon JL, Dowsett SA, et al. Raloxifene use in clinical practice: efficacy and safety. Menopause. 2009;16(2):413–21.

    Article  PubMed  Google Scholar 

  73. Grady D, Ettinger B, Moscarelli E, Plouffe J, Leo SS, Ciaccia A, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol. 2004;104(4):837–44.

    Article  CAS  PubMed  Google Scholar 

  74. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125–37.

    Article  CAS  PubMed  Google Scholar 

  75. Recker RR, Mitlak BH, Ni X, Krege JH. Long-term raloxifene for postmenopausal osteoporosis. Curr Med Res Opinion. 2011;27(9):1755–61.

    Article  Google Scholar 

  76. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41.

    Article  CAS  PubMed  Google Scholar 

  77. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349(13):1216–26.

    CAS  PubMed  Google Scholar 

  78. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722–33.

    Article  CAS  PubMed  Google Scholar 

  79. Leder BZ, O’Dea LSL, Zanchetta JR, Kumar P, Banks K, McKay K, et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metabol. 2015;100(2):697–706.

    Article  CAS  Google Scholar 

  80. Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375:1532–43.

    Article  CAS  PubMed  Google Scholar 

  81. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377:1417–27.

    Article  CAS  PubMed  Google Scholar 

  82. Khosla S, Shane E. A crisis in the treatment of osteoporosis. J Bone Miner Res. 2016;31(8):1485–7.

    Article  PubMed  Google Scholar 

  83. Covello VT, Milligan PA. Risk Communication: principles, tools and techniques. https://www.nrc.gov/docs/ML1015/ML101590283.pdf. Accessed 8 May 2019.

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University Health Network/University of Toronto, Toronto, ON, Canada

    Lianne Tile & Angela M. Cheung

Authors
  1. Lianne Tile
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angela M. Cheung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angela M. Cheung .

Editor information

Editors and Affiliations

  1. Massachusetts General Hospital, Boston, MA, USA

    Benjamin Z. Leder

  2. Massachusetts General Hospital, Boston, MA, USA

    Marc N. Wein

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tile, L., Cheung, A.M. (2020). Safety Considerations for Osteoporosis Therapies. In: Leder, B., Wein, M. (eds) Osteoporosis. Contemporary Endocrinology. Humana, Cham. https://doi.org/10.1007/978-3-319-69287-6_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-69287-6_24

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-319-69286-9

  • Online ISBN: 978-3-319-69287-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation